| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.0037 | 1 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | 0.0015 | 1 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.0013 | 1 |